GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
GreenLight Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Get
GreenLight Biosciences alerts:
Analyst Recommendations
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and iTeos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
GreenLight Biosciences presently has a consensus target price of $4.50, indicating a potential upside of 278.15%. iTeos Therapeutics has a consensus target price of $34.00, indicating a potential upside of 60.68%. Given GreenLight Biosciences' higher probable upside, analysts plainly believe GreenLight Biosciences is more favorable than iTeos Therapeutics.
Valuation and Earnings
This table compares GreenLight Biosciences and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
| iTeos Therapeutics | $344.77 million | 2.18 | $214.52 million | $6.88 | 3.08 |
iTeos Therapeutics has higher revenue and earnings than GreenLight Biosciences.
Profitability
This table compares GreenLight Biosciences and iTeos Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| GreenLight Biosciences | N/A | -195.71% | -45.30% |
| iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
Institutional & Insider Ownership
23.9% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 94.7% of iTeos Therapeutics shares are owned by institutional investors. 6.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats GreenLight Biosciences on 8 of the 10 factors compared between the two stocks.
About GreenLight Biosciences
(Get Rating)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
About iTeos Therapeutics
(Get Rating)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
